Atypical aging in Down syndrome

Topic: Genetics and APOE

At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979 through 2003, the birth prevalence of DS rose from 9.0 to 11.8 (31.1%) per 10,000 live births in 10 representative US regions. This increase, largely due to women conceiving after age 35, portends an ever-growing population of people with DS who may be subject to pathogenic aging. Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes. While longevity in people with DS has improved appreciably in as modest a period as 30 years, age-specific risk for mortality still is considerably increased compared both with other people with ID or with the typically developing population. The penetrance of the phenotype is widely distributed, even though a consistent genotype is assumed in 95% of the cases. Some, but not all body systems, exhibit signs of premature or accelerated aging. This may be due to both genetic and epigenetic inheritance. We now know that the long-term outcome for people with DS is not as ominous as once contemplated; a number of people with DS are living into their late 60s and 70s with few if any major signs of pathogenic aging. Alzheimer's disease (AD), a devastating disease that robs a person of their memory, abilities and personality, is particularly common in elder adults with DS, but is not a certainty as originally thought, some 20% to 30% of elder adults with DS might never show any, or at most mild signs of AD. DS has been called a mature well-understood syndrome, not in need of further research or science funding. We are only beginning to understand how epigenetics affects the phenotype and it may be feasible in the future to alter the phenotype through epigenetic interventions. This chapter is divided into two sections. The first section will review typical and atypical aging patterns in somatic issues in elder adults with DS; the second section will review the multifaceted relationship between AD and DS.

Key findings

• At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging.

Study details

• Participants210,000
• Effect size31.1%
• Evidence strengthLow

Read the original

• DOI: 10.1002/ddrr.1128
• PubMed: 23949829
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{zigman2013-23949829,
  author  = {Zigman, W. B.},
  title   = {{Atypical aging in Down syndrome}},
  journal = {Developmental disabilities research reviews},
  year    = {2013},
  doi     = {10.1002/ddrr.1128},
  pmid    = {23949829},
  url     = {https://doi.org/10.1002/ddrr.1128}
}

Related studies in Down syndrome and Alzheimer's

• Factors Associated with Atypical Cognitive Trajectories in Older Adults with Down Syndrome Alzheimer s & Dementia · 2025-12-01 · usefulness score 45/100
• Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome JAMA neurology · 2018-11-01 · usefulness score 61/100
• Shaping down syndrome brain cognitive and molecular changes due to aging using adult animals from the Ts66Yah murine model Neurobiology of disease · 2024-05-04 · usefulness score 55/100
• Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer disease, and Down syndrome Acta neuropathologica · 2001-11-28 · usefulness score 48/100
• Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis Frontiers in aging neuroscience · 2018-06-21 · usefulness score 47/100
• The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015-06-13 · usefulness score 45/100

Similar studies

• The importance of understanding individual differences in Down syndrome 2016 · Down syndrome and Alzheimer's
• Alzheimer's disease in Down syndrome: neurobiology and risk 2007 · Down syndrome and Alzheimer's
• Down syndrome and Alzheimer's disease: Common pathways, common goals 2015 · Down syndrome and Alzheimer's
• Down's syndrome 2003 · Risk factors
• Neurological phenotypes for Down syndrome across the life span 2012 · Digital health tools
• Multiple morbidity across the lifespan in people with Down syndrome or intellectual disabilities: a population-based cohort study using electronic health records 2023 · Digital health tools

More on Down syndrome and Alzheimer's

• A review that covers this ground Down syndrome and Alzheimer's disease: a link between development and aging Mental retardation and developmental disabilities research reviews · 2001-01-01 · usefulness score 41/100
• Newest in this subject Differential endothelial cell remodeling in Down syndrome and APP duplication drives distinct blood brain barrier dysfunction bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Memory and Plasma pTau217 Refine Prognosis in Down Syndrome Annals of neurology · 2026-10-02 · Peer-reviewed · usefulness score 47/100

See all studies in Down syndrome and Alzheimer's →